-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the Qinghai Provincial Drug Purchasing Center issued the "Notice on Adjusting the Prices of Some Drugs"
.
The notice shows that, after adjustment, the prices of Triptorelin Acetate for Ipsen Injection and Pranoprofen Eye Drops of Zhongsheng Pharmaceutical have dropped
.
On the same day, the Qinghai Provincial Drug Procurement Center also issued the "Notice on Adjusting the Prices of Some Medical Consumables"
.
Among them, single-use interventional accessories (pressure extension tube), single-use interventional accessories (multi-connection three-way), single-use interventional accessories, thrombus aspiration catheter, peripheral balloon dilatation catheter under the knee, PTA balloon dilation catheter, The cutting balloon system, pressure pump, and single-use sheath are all reduced in price
.
It is worth mentioning that the price of the peripheral balloon dilatation catheter under the knee has dropped by nearly 1,100 yuan
.
It is worth noting that it is found that not only Qinghai Province has recently issued a notice of "price reduction of drugs and consumables", but many provinces have also issued relevant notices, and a large number of best-selling drugs and medical consumables are ushering in price reductions
.
For example, on February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions
.
The notice shows that Yunnan Mining Center has received active price reduction applications from 21 companies including Shanghai Pharmaceutical Holdings, Chia Tai Tianqing, Jiangsu Hansen, and CSPC.
The prices of 78 medicines including Sedronate Sodium Tablets, Penicillin V Potassium Tablets, Paclitaxel Injection, and Lenvatinib Mesylate Capsules were reduced
.
Among them, from the perspective of price reduction, there are many varieties with larger declines
.
For example, Bengbu Fengyuan Tushan Pharmaceutical's 150mg ranitidine hydrochloride capsules dropped from 45 yuan to 22.
49 yuan, a drop of as much as 50%
.
In mid-February, Dongguan also officially implemented the group procurement of four types of medical consumables, including coronary guide catheters, coronary guide wires, hemorrhoid staplers, and tubular/end-to-end staplers.
23 public medical institutions in the city participated in the report.
The total number of tasks reached 18,000
.
Among the selected products, the average reduction of coronary catheter and guide wire is over 33%; the average reduction of stapler is over 85%
.
On February 7, the Jiangsu Provincial Public Resource Trading Center issued a notice that the supply prices of 34 drugs produced by 28 pharmaceutical companies will be adjusted, including ceftriaxone sodium for injection from Chengdu Yuandong and methanesulfonic acid from Nanjing Chia Tai Tianqing.
Lenvatinib capsules, Qilu Pharmaceutical's brimonidine tartrate eye drops, Nanjing Yiheng's glipizide controlled-release tablets and other commonly used clinical varieties
.
In terms of price cuts, some products have been cut by more than half.
For example, CSPC Ouyi's bortezomib for injection dropped by as much as 75.
17%, and Jiangsu Enhua's duloxetine hydrochloride enteric-coated capsules dropped by 59.
1%
.
From the above point of view, the industry believes that with the continuous advancement of centralized drug procurement organized by the state, the reshuffle of the pharmaceutical market has accelerated, and the competition among pharmaceutical companies has become more and more fierce; , and is becoming more and more frequent
.
In this context, analysts believe that pharmaceutical companies need to speed up the research and development of innovative products, have competitive products with core competitiveness, make every effort to do a good job in consistency evaluation, and actively participate in the centralized procurement of national and provincial drugs in order to have more market opportunities.
initiative
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The notice shows that, after adjustment, the prices of Triptorelin Acetate for Ipsen Injection and Pranoprofen Eye Drops of Zhongsheng Pharmaceutical have dropped
.
On the same day, the Qinghai Provincial Drug Procurement Center also issued the "Notice on Adjusting the Prices of Some Medical Consumables"
.
Among them, single-use interventional accessories (pressure extension tube), single-use interventional accessories (multi-connection three-way), single-use interventional accessories, thrombus aspiration catheter, peripheral balloon dilatation catheter under the knee, PTA balloon dilation catheter, The cutting balloon system, pressure pump, and single-use sheath are all reduced in price
.
It is worth mentioning that the price of the peripheral balloon dilatation catheter under the knee has dropped by nearly 1,100 yuan
.
It is worth noting that it is found that not only Qinghai Province has recently issued a notice of "price reduction of drugs and consumables", but many provinces have also issued relevant notices, and a large number of best-selling drugs and medical consumables are ushering in price reductions
.
For example, on February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions
.
The notice shows that Yunnan Mining Center has received active price reduction applications from 21 companies including Shanghai Pharmaceutical Holdings, Chia Tai Tianqing, Jiangsu Hansen, and CSPC.
The prices of 78 medicines including Sedronate Sodium Tablets, Penicillin V Potassium Tablets, Paclitaxel Injection, and Lenvatinib Mesylate Capsules were reduced
.
Among them, from the perspective of price reduction, there are many varieties with larger declines
.
For example, Bengbu Fengyuan Tushan Pharmaceutical's 150mg ranitidine hydrochloride capsules dropped from 45 yuan to 22.
49 yuan, a drop of as much as 50%
.
In mid-February, Dongguan also officially implemented the group procurement of four types of medical consumables, including coronary guide catheters, coronary guide wires, hemorrhoid staplers, and tubular/end-to-end staplers.
23 public medical institutions in the city participated in the report.
The total number of tasks reached 18,000
.
Among the selected products, the average reduction of coronary catheter and guide wire is over 33%; the average reduction of stapler is over 85%
.
On February 7, the Jiangsu Provincial Public Resource Trading Center issued a notice that the supply prices of 34 drugs produced by 28 pharmaceutical companies will be adjusted, including ceftriaxone sodium for injection from Chengdu Yuandong and methanesulfonic acid from Nanjing Chia Tai Tianqing.
Lenvatinib capsules, Qilu Pharmaceutical's brimonidine tartrate eye drops, Nanjing Yiheng's glipizide controlled-release tablets and other commonly used clinical varieties
.
In terms of price cuts, some products have been cut by more than half.
For example, CSPC Ouyi's bortezomib for injection dropped by as much as 75.
17%, and Jiangsu Enhua's duloxetine hydrochloride enteric-coated capsules dropped by 59.
1%
.
From the above point of view, the industry believes that with the continuous advancement of centralized drug procurement organized by the state, the reshuffle of the pharmaceutical market has accelerated, and the competition among pharmaceutical companies has become more and more fierce; , and is becoming more and more frequent
.
In this context, analysts believe that pharmaceutical companies need to speed up the research and development of innovative products, have competitive products with core competitiveness, make every effort to do a good job in consistency evaluation, and actively participate in the centralized procurement of national and provincial drugs in order to have more market opportunities.
initiative
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
